Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled date : 2021 - 10 - 12 save search
Corium Receives March 11, 2022 PDUFA Date for New Drug Application for ADLARITY® Patch (donepezil transdermal system) for Treatment of Patients with Alzheimer's Disease
Published: 2021-10-12 (Crawled : 14:15) - biospace.com/
HTGC 4 | $18.96 0.58% 0.0% 620K
|
Finance
|
| O: -0.06%
H: 0.64%
C: -0.29%
new drug disease alzheimer treatment pdufa drug alzheimer’s transdermal system alzheimer's disease alzheimer's
Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis Patients
Published: 2021-10-12 (Crawled : 14:00) - ir.hoththerapeutics.com
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 0.0%
H: 12.17%
C: 0.87%
treatment dermatitis trial approval atopic dermatitis xin
Rejuveron leads EUR 15.7 million Series B investment in Rejuvenate Biomed to accelerate clinical development of its sarcopenia treatment for healthy aging
Published: 2021-10-12 (Crawled : 14:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.16%
H: 0.11%
C: -1.44%
treatment
Astria Therapeutics to Present Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit
Published: 2021-10-12 (Crawled : 13:15) - biospace.com/
ATXS | $9.02 -6.43% -6.87% 660K
|
Manufacturing
|
| O: 0.0%
H: 5.68%
C: 4.47%
disease treatment rare hereditary angioedema
Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Published: 2021-10-12 (Crawled : 13:00) - biospace.com/
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 2.57%
H: 0.0%
C: -2.82%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.22%
H: 2.27%
C: 1.35%
treatment cancer trial enroll
Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Published: 2021-10-12 (Crawled : 12:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 2.57%
H: 0.0%
C: -2.82%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.22%
H: 2.27%
C: 1.35%
treatment cancer trial enroll
Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results
Published: 2021-10-12 (Crawled : 12:15) - biospace.com/
WINT | $5.085 -10.53% -11.77% 51K
|
Health Technology
|
| O: 1.3%
H: 1.28%
C: -2.56%
treatment eye cardiologists results drug research cardio
Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer
Published: 2021-10-12 (Crawled : 12:00) - globenewswire.com
TARA | $2.81 -6.33% -6.76% 420K
|
Health Technology
|
| O: 15.1%
H: 2.33%
C: -2.82%
new drug fda clearance treatment fda cancer drug clearance bladder
Achilles Therapeutics to join the Northern Alliance Advanced Therapy Treatment Centre consortium
Published: 2021-10-12 (Crawled : 12:00) - globenewswire.com
ACHL | $0.7764 -0.6% -0.61% 120K
|
Manufacturing
| Email alert
Add to watchlist
treatment therapy
Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Published: 2021-10-12 (Crawled : 12:00) - biospace.com/
DCPH | $14.6 -0.48% -0.48% 320K
|
Health Technology
|
| O: 0.19%
H: 7.51%
C: 6.61%
treatment test gastrointestinal switzerland approval
Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results from its Istaroxime ECS Study
Published: 2021-10-12 (Crawled : 12:00) - globenewswire.com
WINT | $5.085 -10.53% -11.77% 51K
|
Health Technology
|
| O: 1.3%
H: 1.28%
C: -2.56%
treatment eye cardiologists results drug research cardio
NanoString Launches nCounter Antibody Drug Conjugate Panel to Accelerate the Development of Oncology Treatments
Published: 2021-10-12 (Crawled : 11:00) - biospace.com/
NSTG M | $0.1053 -37.43% -0.19% 0
|
Health Technology
|
| O: 1.41%
H: 3.59%
C: 1.5%
treatment antibody drug
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.